Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies

• DOI: 10.1080/14712598.2024.2316180
• Publication Date: 2024-02-07T07:35:35Z
• Authors: Antonio Tursi; Giammarco Mocci; Angelo Del Gaudio; Alfredo Papa
• Keywords: Ustekinumab; Vedolizumab; Biosimilar

The therapeutic armamentarium for managing Crohn's disease (CD) has expanded significantly in recent decades. Several biologics with three different mechanisms of action [anti-tumor necrosis factor (TNF)-α, anti-integrin α4β7, and anti-IL 12/23] are currently available to manage CD.